ArticleFrontiers in immunology2013
Bacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applications.
Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 85 citations in OpenAlex.
- Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.American journal of respiratory and critical care medicine · 2019Trial
- Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTAFrontiers in immunology · 2026Article
- Recent Advancements in Non-Invasive Vaccination Strategies.Vaccines · 2025Review
- Natural peptidoglycan nanoparticles enable rapid antigen purification and potent delivery of plant-derived vaccines.Plant communications · 2025Article
- Gram-positive enhancer matrix delivering FVpE via M cell targeting elicit protective mucosal and adaptive immune responses againstFrontiers in immunology · 2025Article
- Article
- Immunogenicity and protective efficacy of a novel bacterium-like particle-based vaccine displaying canine distemper virus antigens in mice and dogs.Microbiology spectrum · 2024Article
- Article
- Group A Streptococcus Pili-Roles in Pathogenesis and Potential for Vaccine Development.Microorganisms · 2024Review
- A novel bacterium-like particles platform displaying antigens by new anchoring proteins induces efficacious immune responses.Frontiers in microbiology · 2024Article
- A gram-positive enhancer matrix particles vaccine displaying swine influenza virus hemagglutinin protects mice against lethal H1N1 viral challenge.Frontiers in immunology · 2024Article
- Oral delivery of bi-autoantigens by bacterium-like particles (BLPs) against autoimmune diabetes in NOD mice.Drug delivery · 2023Article
- Posterity of nanoscience as lipid nanosystems for Alzheimer's disease regression.Materials today. Bio · 2023Review
- Development and Immunoprotection of Bacterium-like Particle Vaccine against Infectious Bronchitis in Chickens.Vaccines · 2023Article
- Antigen Delivery Systems: Past, Present, and Future.Biomolecules & therapeutics · 2023Review
- Recent Advances in Inhaled Nanoformulations of Vaccines and Therapeutics Targeting Respiratory Viral Infections.Pharmaceutical research · 2023Review
- Intranasally inoculated bacterium-like particles displaying porcine epidemic diarrhea virus S1 protein induced intestinal mucosal immune response in mice.Frontiers in immunology · 2023Article
- Bacterium-like particles derived from probiotics: progress, challenges and prospects.Frontiers in immunology · 2023Review
- The adjuvant effect of bacterium-like particles depends on the route of administration.Frontiers in immunology · 2023Article
- A novel, non-GMO surface display in Limosilactobacillus fermentum mediated by cell surface hydrolase without anchor motif.BMC microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The successful development of a mucosal vaccine depends critically on the use of a safe and effective immunostimulant and/or carrier system. This review describes the effectiveness and mode of action of an immunostimulating particle, derived from bacteria, used in mucosal subunit vaccines. The non-living particles, designated bacterium-like particles are based on the food-grade bacterium Lactococcus lactis. The focus of the overview is on the development of intranasal BLP-based vaccines to prevent diseases caused by influenza and respiratory syncytial virus, and includes a selection of Phase I clinical data for the intranasal FluGEM vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.